Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478202 | 1.00 | IDO1 (0.46) | IDO1KDM4ETSHRLMNAMAPT | |
| SCHEMBL31399738 | 0.78 | PLAU (0.54) | KDM4ETSHRLMNAMAPTTP53 | |
| SCHEMBL31165762 | 0.78 | KDM4E (0.43) | IDO1KDM4ETSHRLMNAMAPT | |
| SCHEMBL14250663 | 0.78 | PLAU (0.54) | KDM4ETSHRLMNAMAPTTP53 | |
| SCHEMBL12055258 | 0.78 | KDM4E (0.44) | IDO1KDM4ETSHRLMNAMAPT | |
| SCHEMBL160843 | 0.78 | CYP2A6 (0.54) | KDM4ETSHRLMNAMAPTTP53 | |
| SCHEMBL5663372 | 0.78 | MAPT (0.53) | IDO1KDM4ETSHRLMNAMAPT | |
| SCHEMBL1564280 | 0.78 | CYP2A6 (0.50) | IDO1KDM4ETSHRLMNAMAPT | |
| SCHEMBL12055251 | 0.78 | CYP1A2 (0.54) | KDM4ETSHRLMNAMAPTTP53 | |
| SCHEMBL13537368 | 0.78 | KDM4E (0.43) | IDO1KDM4ETSHRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 764 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4679087-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| WO-2024190663-A1 | BIOMARKER AND USE THEREOF | 株式会社明治 | 2024-09-19 | — | — | WO | claimed |
| US-10675351-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-06-09 | — | — | US | claimed |
| CN-109793735-A | Application of the PARP-1 inhibitor in preparation treatment iron overload disease medicament | 浙江大学 | 2019-05-24 | — | — | CN | claimed |
| US-20190117663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIV CASE WESTERN RESERVE (US) | 2019-04-25 | — | — | US | claimed |
| EP-3412279-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | The Brigham and Women's Hospital, Inc. (US) | 2018-12-12 | — | — | EP | claimed |
| US-9974859-B2 | Nanostructured gels capable of controlled release of entrapped agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-05-22 | — | — | US | claimed |
| WO-2018022494-A1 | REPURPOSING CANCER DRUGS FOR TREATMENT OF MYCOBACTERIUM | STC.UNM (US) | 2018-02-01 | — | — | WO | claimed |
| WO-2017176756-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-12 | — | — | WO | claimed |
| US-9623008-B2 | Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers | STC.UNM (US) | 2017-04-18 | — | — | US | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| US-5657064-A | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION (US) | 1997-08-12 | — | — | US | claimed |
| US-5589483-A | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence | GERON CORPORATION (US) | 1996-12-31 | — | — | US | claimed |
| US-5587384-A | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity | THE JOHNS HOPKINS UNIVERSITY (US) | 1996-12-24 | — | — | US | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0673782-A2 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| WO-1995020952-A1 | INHIBITORS OF POLY(ADP-RIBOSE) SYNTHETASE AND USE THEREOF TO PREVENT NMDA NEUROTOXICITY | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-08-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PARP2, PARP1, PPP2CA | IDO1 3308/4885KDM4E 1304/4885TSHR 4537/4885 |
| US-10675351-B2 | Nanostructured gels capable of controlled release of encapsulated agents | MMP2, CEL, LIPA | IDO1 3851/4885KDM4E 3867/4885TSHR 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.